FIELD: medicine.
SUBSTANCE: method involves applying cannabinoid receptor agonists for treating for transitory relaxation of lower esophageal sphincter and states like gastroesophageal reflux disease, regurgitation, preventing reflux or insufficient mass increase caused by the relaxation.
EFFECT: enhanced effectiveness of treatment.
18 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTAGONISTS OF METBOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) AND METHODS OF PREVENTION AND TREATMENT OF GASTROESOPHAGEAL REFLUX (OPTIONS) | 2003 |
|
RU2324484C2 |
| DRUG FROM GASTROESOPHAGEAL REFLUX DISEASE | 2013 |
|
RU2635766C2 |
| REFLUX INHIBITORS | 1997 |
|
RU2199316C2 |
| METHOD OF TREATING GASTROESOPHAGEAL REFLUX | 2014 |
|
RU2558849C1 |
| METHOD FOR REPAIRING ANTIREFLUX FUNCTION LOWER ESOPHAGEAL SPHINCTER | 2005 |
|
RU2277946C1 |
| DEVICE FOR INJECTION THERAPY OF GASTROESOPHAGEAL REFLUX DISEASE | 2011 |
|
RU2514093C2 |
| METHOD OF TREATING NONEROSIVE GASTROESOPHAGEAL REFLUX DESEASE | 2012 |
|
RU2480255C1 |
| METHOD OF ABATEMENT OF HEARTBURN AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) BY MEANS OF SPECIAL POLYSACCHARIDES | 2007 |
|
RU2432167C2 |
| METHOD FOR TREATING GASTROESOPHAGEAL REFLUX CASES | 2006 |
|
RU2318550C1 |
| METHOD OF TREATMENT OF LARYNGOPATHY CAUSED BY GASTROESOPHAGEAL REFLUX | 2007 |
|
RU2346711C1 |
